Physician profile
Roger Esper
NPI 1568429280
$521.12
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $42.98 · 2021: $231.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.71 | 2021 | |
| Glaxosmithkline, LLC. | $123.72 | 2019 | |
| Merck Sharp & Dohme LLC | $62.94 | 2019-2021 | |
| Abbott Laboratories | $49.02 | 2019 | |
| Pfizer INC. | $31.20 | 2020 | |
| Allergan, INC. | $27.33 | 2019-2020 | |
| Lilly USA, LLC | $16.29 | 2021 | |
| Amarin Pharma, INC. | $16.19 | 2019 | |
| Sanofi Pasteur INC. | $11.90 | 2019 | |
| Acadia Pharmaceuticals INC | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Esper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.